Company news
Alumis Inc. (NASDAQ:ALMS) news
Every Alumis Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
August 13, 2026
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin ...
August 10, 2026
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
May 14, 2026
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Tr...
March 28, 2026
Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements
March 19, 2026
Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 America...
March 18, 2026
Alumis to Present at the Leerink Partners Global Healthcare Conference
March 2, 2026
Alumis to Participate in Upcoming February Investor Conferences
February 5, 2026
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 9, 2026
Alumis Announces Pricing of Upsized Public Offering of Common Stock
January 7, 2026
Alumis Announces Proposed Public Offering of Common Stock
January 6, 2026
Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 6, 2026
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis
January 5, 2026
Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
November 13, 2025
Alumis to Participate in Upcoming November Investor Conferences
November 4, 2025
Alumis to Participate in Upcoming September Investor Conferences
August 29, 2025
Alumis Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatmen...
July 24, 2025
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary
July 14, 2025
Alumis to Present at the Jefferies Global Healthcare Investor Conference
May 29, 2025
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Ora...
May 29, 2025
Alumis Completes Merger with ACELYRIN
May 21, 2025
Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements
May 14, 2025
Alumis Stockholders Approve Merger with ACELYRIN
May 13, 2025
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commerciali...
May 13, 2025
Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis
May 6, 2025
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
May 1, 2025
Alumis and ACELYRIN Announce Amended Merger Agreement
April 21, 2025
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
April 4, 2025
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
March 25, 2025
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
March 19, 2025
Alumis to Present at Leerink's 2025 Global Healthcare Conference
March 10, 2025
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
March 8, 2025
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
March 4, 2025
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
March 4, 2025
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposa...
March 4, 2025
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annu...
February 28, 2025
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibito...
February 27, 2025
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
February 20, 2025
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 10, 2025
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Tra...
February 6, 2025
Alumis Strengthens Leadership Team with Key Appointments
January 28, 2025
Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005
December 19, 2024
Alumis Presents Data Highlighting ESK-001’s Potential as a High-efficacy Oral Treatment for Systemic Lupus Erythematosus (SLE) at ACR Con...
November 14, 2024
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
November 13, 2024
Alumis to Participate in Guggenheim's Inaugural Healthcare Innovation Conference
November 4, 2024
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sust...
September 27, 2024
Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements
August 13, 2024
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
July 29, 2024